At the 1st Global Forum on Bacterial Infections we’ll be piloting “hands-on sessions” focused on the more practical aspects of containing antibiotic resistance. These workshops for researchers, clinicians, and policymakers are designed to be small, intensive, and interactive. Space is limited, so we’ve opened up pre-registration on the Global Forum website (click on a hands-on session and you’ll see the form to sign up). There are six se
As you may recall, a study on the environmental dissemination of NDM-1 in India in last month’s Lancet Infectious Diseases caused a storm of controversy. NDM-1, first documented in 2008, is a gene that confers resistance to our most powerful class of antibiotics – carbapenems. The tremendous challenge in treating infections caused by bacteria containing the NDM-1 gene is naturally a cause for concern in the global health community.
Anticipating World Health Day on April 7th, The Economist has tackled the issue of antibiotic resistance, finding the urgency of the problem largely a result of a "tragedy of the commons" and a lack of sufficient incentives for individual actors to conserve antibiotic therapies. As in, patients looking for a quick fix do not have much of an incentive to think about the long-term consequences when they take antibiotic
CDDEP staffers have been hard at work recently on the 1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance, a collaborative meeting co-organized by CDDEP and the Public Health Foundation of India (PHFI). The Global Forum will be the first of its kind to focus on issues of treatment access and antibiotic resistance in low- and middle-income countries.
How to best control resistance is a controversial matter. Existing recommendations do not always agree and some recommendations are conflicting. One clear example is the key components of the Swedish intervention mentioned in Maya's recent post—isolation and contact tracing. In this specific study, children were isolated from day-care, sometimes up to a year.
We recently launched the Global Antibiotic Resistance Partnership (GARP) to extend the work of Extending the Cure to five developing countries - China, India, Kenya, South Africa and Vietnam. Although these countries do not use antibiotics at nearly the intensity that one sees in the United States, they already face high levels of resistance, particularly in hospital-acquired infections.
A two-month-old black rhino toddles unsteadily into the clearing to adoring oohs and aahs, her back protected from the bright sun by a red cloth, white salve on her ears to help heal some rough spots, and a gentle and patient guide beside her. This Kenyan baby will be nurtured for two more years at this suburban preserve before release into the wilds of Tsavo National Park. At that point, a normal lifespan’s survival would be nearly assured, despite having been abandoned by her mother for reasons we’ll never know, possibly after a premature birth.
We tend to think of antibiotic resistance somewhat parochially as the problem that exists in the United States, and possibly in other high-income countries.